Xilio Therapeutics, Inc.
NASDAQ:XLOBiotechnology
+$0.45 today
- Market cap
- $53.90M
- Beta
- -0.09
- P/E (TTM)
- -48.1
- EPS (TTM)
- -$0.19
Volume 0.01M
Average 0.05M
XLO Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Xilio Therapeutics, Inc.NASDAQ: XLO
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $9.53M (cash outflow) fell 28.2% year over year, ahead of the -42.4% change in trailing-twelve-month net income. Over 3 fiscal years it compounded at -26.5% a year.
Context
- Net income amounted to 80.1% of revenue in FY2025, down 838.0 pp from a year earlier.
- Net income grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$18.98M (-45.8%) for the fiscal year ending Dec 2026, a slowdown from the -39.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$9.53M-192.0% QoQ
- Last fiscal yearDec 2025
- -$35.04M-39.8% YoY
- LTMMar 2026
- -$31.3M-42.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -28.2% | -26.7% | +1.5 pp |
| 1 year | -39.8% | -45.8% | -6.0 pp |
| 3-year CAGR | -26.5% | -16.1% | +10.4 pp |
| 5-year CAGR | -11.2% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (35.04M) USD
- Year-over-year change
- +39.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (35.04M) | +39.8% |
| FY2024 | 2024-12-31 | (58.24M) | +23.8% |
| FY2023 | 2023-12-31 | (76.4M) | +13.4% |
| FY2022 | 2022-12-31 | (88.22M) | -16.4% |
| FY2021 | 2021-12-31 | (75.8M) | — |
Net Income vs competitors
How XLO compares with its peers on the latest reported figures
- XLO's LTM Mar 2026 net income of $31.3M is the 3rd largest of the 4 companies compared; the peer median is $11.31M.
- Its year-over-year change of -42.4% is the lowest of 4, against a peer median of +127.6%.
- Net income amounts to 58.5% of revenue for XLO, versus a peer median of 32.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $18.8B | +53055.5% | +845.2% | — | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | $58.75M | -23.5% | +26.3% | — |
| LTM Mar 2026 | $31.3M | -42.4% | -26.5% | 58.5% | |
| LTM Jun 2026 | $11.31M | +127.6% | +0.9% | 32.2% | |
| Peer median (excluding XLO) | $11.31M | +127.6% | +26.3% | 32.2% | |
Competitors are the stored peer set for XLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (75.8M) | (88.22M) | (76.4M) | (58.24M) | (35.04M) |
| Depreciation & Amortization | 1.5M | 1.85M | 1.9M | 1.64M | 1.54M |
| Deferred Income Tax | 222K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.96M | 8.42M | 7.38M | 6.43M | 6.94M |
| Change in Working Capital | (11.8M) | 2M | (1.66M) | 31.78M | 25.13M |
| Accounts Receivables | 0 | 0 | 0 | 0 | (5M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (2.82M) | 485K | (2.06M) | 1.53M | 152K |
| Other Working Capital | (8.99M) | 1.52M | 405K | 30.26M | 29.97M |
| Other Non-Cash Items | 173K | 224K | 160K | 3K | (3.56M) |
| Operating Cash Flow | (80.75M) | (75.72M) | (68.62M) | (18.38M) | (4.99M) |
| Capital Expenditures | (1.1M) | (1.87M) | (486K) | (36K) | (518K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (1.1M) | (1.87M) | (486K) | (36K) | (518K) |
| Debt Repayment | (110K) | (85K) | (6.75M) | (3.38M) | 0 |
| Common Stock Issued | 116.36M | 16K | 202K | 6.83M | 87.78M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (467K) | 0 | 0 | 25.75M | 0 |
| Financing Cash Flow | 260.67M | (69K) | (6.55M) | 29.2M | 87.78M |
| Effect of Forex Changes | 0 | (9K) | (25K) | 0 | 0 |
| Net Change in Cash | 178.82M | (77.67M) | (75.68M) | 10.78M | 82.27M |
| Free Cash Flow | (81.85M) | (77.59M) | (69.11M) | (18.41M) | (5.51M) |
Xilio Therapeutics, Inc.
NASDAQ:XLO
Intrinsic Alpha fair value
Locked
Current Price
$7.63
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.